Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed advanced solid tumor

- Refractory disease

- Patients must have been offered and refused OR received and failed prior
treatment with all standard or approved therapies for the malignancy

- Measurable or evaluable disease as confirmed by radiographic or clinical evidence

- No curative therapy available

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Life expectancy ≥ 3 months

- ANC > 1,500/mm³

- Platelet count > 75,000/mm³

- Hemoglobin ≥ 9.0 g/dL

- Creatinine ≤ 2.0 mg/dL

- AST and ALT < 3 times upper limit of normal

- Not pregnant

- No nursing during and for ≥ 28 days after completion of study treatment

- Two negative pregnancy tests required

- Fertile women must use effective double-method contraception for ≥ 28 days before,
during, and for ≥ 28 days after completion of study treatment

- Men must use a latex condom during sexual contact with fertile females during and for
≥ 28 days after completion of study treatment, even if a prior successful vasectomy
was performed

- Stable neurological exam

- No serious medical condition or psychiatric illness that would preclude study
participation

- No prior desquamating rash or allergic reaction ≥ grade 2 while taking thalidomide,
lenalidomide, or structurally related compounds

- No peripheral neuropathy ≥ grade 2

- No active infection

- No uncontrolled hyper- or hypocalcemia, glycosemia, or thyroidism

PRIOR CONCURRENT THERAPY:

- No prior CC-4047

- More than 28 days since prior cytotoxic chemotherapy (42 days for nitrosoureas)

- At least 14 days since prior therapeutic radiotherapy

- More than 14 days since prior thalidomide, lenalidomide, or structurally related
compounds

- More than 14 days since prior biological response modifier therapy

- Concurrent radiotherapy to treat pain associated with existing bone lesions during
the extension phase of the study allowed provided < 10% of bone marrow is irradiated

- Concurrent systemic steroids for control of CNS primary tumor and/or metastases
symptoms allowed provided dose is stable or decreasing AND patient is also taking
low-dose aspirin and/or other platelet-active, anti-thrombotic medication during and
for 30 days after completion of study treatment

- No other concurrent chemotherapy or immunotherapy

- No other concurrent investigational agents

- No concurrent hematopoietic growth factors during the treatment phase of the study

- No other concurrent anticancer agents